Healthcare / Medical Instruments & SuppliesLSE
$381.25
+1.25 (+0.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $8.3M · quality 84.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$183M
P/E
23.8x
↑EV/EBITDA
1585.0x
↑ROE
20.1%
↑Gross Margin
80.6%
↑Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+14.3%
FCF CAGR
+24.2%
FCF margin
17.9%
FCF / Net income
1.26x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $46.5M · net income $6.6M · FCF $8.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $46.5M | $46.5M | $41.9M | $36.0M | $31.1M |
| Net Income | $6.6M | $6.6M | $6.5M | $4.5M | $987000.00 |
| EBITDA | $11.5M | $11.5M | $10.0M | $7.8M | $7.0M |
| EPS | — | — | 0.14 | 0.09 | 0.02 |
| Gross Margin | 80.6% | 80.6% | 80.1% | 77.5% | 80.1% |
| Operating Margin | 21.0% | 21.0% | 16.7% | 14.7% | 5.6% |
| Net Margin | 14.3% | 14.3% | 15.5% | 12.4% | 3.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.18 | 0.18 | 0.18 | 0.17 | 0.20 |
| Current Ratio | 4.13 | 4.13 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $8.3M | $8.3M | $8.7M | $6.1M | $4.3M |
| Returns | |||||
| ROE | 20.1% | 20.1% | 20.0% | 14.5% | 3.3% |
| Valuation | |||||
| P/E | 23.83 | 23.83 | 3412.11 | 3768.74 | 17654.64 |
| EV/EBITDA | 1584.96 | 1584.96 | 2209.04 | 2125.76 | 2348.23 |
| P/B | 551.37 | 551.37 | 682.01 | 543.40 | 551.11 |
| Growth & Yield | |||||
| Revenue Growth | 10.8% | 10.8% | 16.5% | 15.7% | — |
| EPS Growth | — | — | 45.0% | 381.4% | — |
| Dividend Yield | 3.7% | 3.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.2%
Start / end P/E
n/dx → n/dx
EPS bridge
0.14 → n/d
Residual
+10.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.